According to a new report published by Reports Monitor titled, “Chemotherapy Drugs Market by Drugs, Route of Administration, Indication and End-User: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the chemotherapy drugs market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025. North America is expected to contribute significant share of the market and anticipated to continue the trend over the forecast period.
During last decade, cancer treatment has gained a huge attention. Development in technology has introduced the new and advanced treatment options. Chemotherapy is the use of anti-cancer drugs designed to slow or stop the growth of rapidly dividing cancer cells. There are two types of chemotherapy namely: systemic and regional broadly applied against treating various types of cancers. According to WHO in 2012 there were 14 million new cases of cancer and 8.8 million cancer-related deaths occurred worldwide in 2015.
Rising prevalence of various types’ cancer and increased vulnerability to carcinogenic material along with drastically changed sedentary living standards are the aspects majorly driving chemotherapy drug market. Additionally, huge funding availability for research and development, increasing demand for biological and targeted drug therapies, continuous expiry of key cancer drug and accelerated growth of healthcare sector boosts further growth of the market. However high cost of drug development, long time approval, stringent guideline and side effects associated with the treatment may hinder the market growth. Asia-Pacific region is influenced by surging demand for chemotherapy drugs, increasing affecting population, developing healthcare infrastructure and penetrating R&D activates funded by government bodies. The Ministry of Health & Family Welfare Grants offers up to a maximum of Rs. 50,000 to poor patients to assist for hospitalization and treatment in India.
The global chemotherapy market is segmented on the basis of drugs, types, route of drug administration, and end-user. On the basis of drugs, it is segmented into alkylating agents, anti-tumor antibiotics, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and others. On the basis of types, the market is segmented into blood cancer, lung cancer, lymphatic cancer, breast cancer, ovarian cancer, myeloma, and others. On the basis of route of drug administration, the market is segmented into oral and parenteral. On the basis of end-user, it is segmented into hospitals & clinics, research institutes, and others. Competitive landscape
There is huge opportunity for chemotherapy drug market to prosper in coming future. Major players are infiltrating the market by under taking strategies such as merger and acquisition. Prominent players operating in the market include: Sanofi, Novartis, Eli Lilly & Company, Pfizer Inc., AstraZeneca, GlaxoSmithKline, Teva Pharmaceuticals Industries, Bristol-Myers Squibb, Bayer AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc. and Boehringer Ingelheim.
In April, 2017 the US FDA approved the first targeted therapy to treat adults with acute myeloid leukemia. Rydapt works by blocking several proteins on cancer cells including FLT3 that help grow the cancer cells. It is intended to be used along with chemotherapy to treat newly diagnosed adults who have mutation in a gene called FLT3.
About Garner Insights:
We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.